The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1.sup.+, VCAM-1.sup.+, 3-integrin.sup.+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle -actin, nestin, hepatocyte growth factor, stromal derived factor-1 and Hlx homeobox transcriptional factor.

The present invention relates to a method for the preparation of autologous human primary hair follicles in 3D cultures, comprising the isolation of primary fetal follicles; isolation of the patient's hair follicle cells; isolation of skin cells of the patient's scalp; extraction of growth factors from fetal follicle cells; the fibrin gel creation that contains growth factors of fetal follicles; sandwich cultivation of patient's hair follicle cells and skin of the patients scalp on or into fibrin gel that contains growth factors of fetal follicles; separation from fibrin gel the patients primary hair follicles, which can be used to treat baldness as an autologous graft.

This invention provides ex vivo methods for making modified natural killer cell compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof.

The present invention relates to a method for the in vitro selection of at least one therapeutic cell subpopulation from an original cell population of eukaryotic cells, as well as to the therapeutic cell subpopulation selected by the method, which can be used for the treatment of diseases of tissues or organs. The selected cells are highly migrative and the method according to the invention provides for the selection of these highly migrative subpopulations from a sample comprising a mixture of cells.

A method for dynamic evolution and/or adaptation and monitoring of characteristics in living cells is provided, wherein the method may be performed at a microfluidic-enabled cell-culture device comprising pneumatic layer for directing flow of fluid to a plurality of individually addressable wells, and one or more sensors configured to detect data regarding environments inside one or more of the plurality of wells. The method may involve culturing a population of cells in a first well of the plurality of wells, perturbing one or more characteristics of an environment in the first well following the culturing of the population of cells, monitoring one or more characteristics of the population of cells in the first well, and removing all or part of the evolved/adapted population of cells from the first well.

Disclosed herein are bioreactor systems and methods of utilizing said systems.

Described are methods of enhancing development of renal organoids, methods of using the same, and kits.

A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. A method for culturing colorectal cancer solid tumor primary cells and colorectal cancer ascites primary tumor cells and supporting reagents. Colorectal cancer solid tumor tissues are treated with mild cell dissociation reagents, and colorectal cancer cells are isolated from ascites with a mild method, thereby ensuring the vitality of cancer cells to the greatest extent. A special serum-free medium is prepared, and colorectal cancer solid tumor-derived tumor cells are cultured in vitro with a suspension culture system to ensure normal expansion of the cancer cells while eliminating the interference of normal cells to the greatest extent. The colorectal cancer primary cell culture obtained by the method are usable for in vitro experiments, second-generation sequencing, building of animal models, and building of cell lines at multiple cell levels.

Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation for use in the treatment of autoimmune diseases/disorders and/or inflammatory diseases/disorders. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors for use in the treatment of autoimmune diseases/disorders and/or inflammatory diseases/disorders. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CARS).

The present disclosure relates to precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and a preparation method therefor. The precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells of the present disclosure have enhanced functionality and excellent proliferative capacity compared with typical mesenchymal stem cells or induced pluripotent stem cell-derived mesenchymal stem cells.